Search results
Results from the WOW.Com Content Network
On a stand-alone basis, Globus Medical reaffirms its full year 2025 revenue guidance of $2.66 billion to $2.69 billion, and fully diluted non-GAAP earnings per share range between $3.40 to $3.50.
Welcome to Globus Medical's second-quarter 2024 earnings call. [Operator instructions] I'll now turn the call over to Brian Kearns, senior vice president of business development and investor ...
Globus Medical (NYSE:GMED) has had a rough three months with its share price down 11%. But if you pay close attention...
Globus Medical (NYSE: GMED) Q3 2024 Earnings Call ... I will now turn the call over to Brian Kearns, senior vice president of business development and investor relations. ... *Stock Advisor ...
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.
Globus Medical’s orthopedic trauma business is rapidly growing. With these new technologies building out the product portfolio and the continued integration of the PRECICE™ magnetically actuated limb-lengthening nail technologies, there is more capacity to service a wide variety of patient needs with innovative solutions.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Globus Medical's (NYSE:GMED) stock up by 6.0% over the past three months. Given that stock prices are usually aligned...